View all ASCO15 CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations - PER Pulse™ Recaps
Banner Image

Resources

Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations - Online Activity
Earn up to 1.5 AMA PRA Category 1 Credits™
Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations - Online Activity focuses on translating expert perspectives into clinically relevant information that can be applied by physicians in practice. Immuno-oncology is one of the hottest areas in cancer research and drug development. These innovative treatments for cancer may ultimately prove to be game-changers that radically change treatment paradigms for a number of solid tumors we manage. The sheer volume of basic science and therapeutic developments that continue to emerge in this field is immense. This immuno-oncology program is geared to meet the needs of busy oncologists who strive to maintain cutting-edge knowledge in the care of their patients with the most difficult-to-treat tumors.


PER Pulse™ Recap
PER Pulse™ Recap for Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations focuses on immuno-oncology topics likely to be practice-changing for oncologists, immediately or in the near future, including discussion and clinical perspectives on immune checkpoint inhibitors for patients with non-small cell lung cancer, cancers of the head and neck, and mesothelioma.
 



PER Pulse™ Recap

PER Pulse™ Recap

Medical Writer: Beth Cameron, PhD



1 of 3
PER Pulse™ Recap:

Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations

The Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations activity is geared to meet the needs of the busy oncologist striving to maintain cutting-edge knowledge when caring for patients with the most difficult-to-treat tumors. This activity includes short videos with immuno-oncology experts who address a variety of questions for multiple types of tumors, including non–small cell lung cancer (NSCLC), cancers of the head and neck, mesothelioma, and others. This activity was designed to aid physicians in assessing the wealth of emerging data concerning the use of immuno-oncology and applying those findings to their practices.

This recap, which is the first of 3 PER Pulse™ Recaps summarizing the program, consists of expert guidance on immuno-oncology for NSCLC:

  • According to Julie Brahmer, MD, nivolumab is now the standard-of-care for squamous NSCLC following progression on platinum-based therapy. She hopes that nivolumab will be approved by the FDA for nonsquamous histology as well, based on the phase III data recently presented.
  • If a patient has received an EGFR or ALK inhibitor as first-line treatment, Dr Brahmer recommends chemotherapy before recommending nivolumab. She points out that the results of several earlier clinical trials have shown this immunotherapy to be efficacious in later lines of therapy..
  • Dr Brahmer points out that immunotherapies can cause inflammation of any organ in the body, so it is important to have a team able to manage these adverse events and to discuss these possibilities with patients. Also, a minority of patients have what looks to be progression before improvement, so patients that are feeling well on the therapy can still respond and should be considered for further therapy although scans may showing their disease is progressing.


2 of 3
PER Pulse™ Recap:

Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations

Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations activity is geared toward meeting the needs of the busy oncologist who strives to maintain cutting-edge knowledge in the care of patients with the most difficult-to-treat tumors. It includes short videos with immuno-oncology experts who address a variety of questions for multiple types of tumors, including non-small cell lung cancer, cancers of the head and neck, mesothelioma, among others. This activity was designed to aid physicians in assessing the wealth of emerging data concerning the use of immuno-oncology, and in applying those findings to their practices.

This recap, which is the second of 3 PER Pulse™ Recaps summarizing the program, consists of expert guidance on immuno-oncology for squamous cell carcinoma of the head and neck (SCCHN).

  • According to Dr. Barbara Burtness, immune checkpoint inhibitors have enormous potential in treating patients with human papillomavirus (HPV)-positive or HPV-negative recurrent/metastatic SCCHN. The response rates for HPV-negative disease are encouraging because historically it has been difficult to see progress with treatments for this set of patients.
  • Dr. Burtness reports that although overall response rates for patients who are HPV-positive and HPV-negative taking immune checkpoint inhibitors are similar for pembrolizumab, the largest dataset we currently have, the progression-free survival and median duration of response favor the more indolent HPV-positive cancers to some extent.
  • Dr. Julie Brahmer points out that immune checkpoint inhibitors in SCCHN do not have the duration of follow-up that they have in such cancers as melanoma and lung cancer; the pseudo-progression described in some patients with melanoma has not been observed in patients with SCCHN. 

To learn more about the immuno-oncology, including the full responses summarized above, visit www.gotoper.com/online-cme-activities/asco15/transforming-immuno-oncology-across-solid-tumors-targeting-pathways-efficacy-and-combinations-online-activity.



Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

This activity is supported by an educational grant from AstraZeneca.




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728
Filter By